RNS Number : 4449E
Renalytix AI PLC
06 November 2020
Renalytix AI plc
("RenalytixAI" or the "Company")
Change of adviser
NEW YORK, November 6, 2020 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and joint broker, Stifel.
For further information, please contact:
Renalytix AI plc
|
www.renalytixai.com
|
James McCullough, CEO
|
Via Walbrook PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710 7600
|
Alex Price / Nicholas Moore
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597 4000
|
Gary Clarence / Daniel Adams
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
Paul McManus / Lianne Cawthorne
|
Mob: 07980 541 893 / 07584 391 303
|
|
|
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
APPFSLFAIESSESF